c
h
p
e
r
liver
major
bloodfilt
organ
consequ
predispos
bloodborn
infect
caus
infecti
hepat
viral
infect
tend
affect
liver
particular
high
affin
liver
subgroup
virus
term
hepat
virus
group
cover
separ
chapter
book
summar
viral
infect
primarili
target
liver
caus
viral
hepat
part
system
infect
lead
hepat
complic
certain
condit
immunodefici
cours
chapter
replac
clinic
textbook
viral
infect
instead
focus
hepat
aspect
viral
infect
infect
caus
virus
hepat
virus
roughli
classifi
three
major
categori
liver
diseas
patient
fever
return
tropic
subtrop
area
frequent
caus
exot
agent
sever
liver
damag
patient
immunodefici
result
de
novo
infect
exacerb
common
agent
herpesvirus
adenovirus
liver
involv
patient
respiratori
system
infect
frequent
mediat
via
immunolog
mechan
approxim
travel
develop
world
requir
medic
care
travel
fever
underli
problem
physician
evalu
return
travel
fever
frequent
suspect
rare
exot
diagnos
travelassoci
liver
diseas
caus
exot
infect
ebola
viru
rift
valley
fever
lassa
fever
report
sporad
literatur
current
repres
frequent
health
problem
identifi
caus
dengu
among
top
three
etiolog
agent
account
approxim
febril
ill
travel
note
although
malaria
lead
caus
system
febril
ill
worldwid
travel
everi
tropic
subtrop
region
except
subsaharan
africa
central
america
confirm
suspect
dengu
frequent
malaria
chikungunya
emerg
novel
viral
infect
recent
report
asia
africa
caus
fever
promin
myalgia
arthralgia
rash
increas
number
patient
viral
hemorrhag
fever
share
epidemiolog
clinic
featur
caus
rather
similar
liver
patholog
virus
transmit
via
arthropod
vector
variou
virus
caus
damag
small
vessel
multipl
organ
frequent
lead
overt
hemorrhag
spectrum
diseas
geograph
distribut
list
tabl
much
attent
paid
abnorm
liver
function
alter
hepat
patholog
nevertheless
clinic
signific
liver
diseas
death
liver
failur
rare
complic
except
patient
yellow
fever
dengu
viru
complex
consist
four
antigen
relat
distinct
flavivirus
term
dengu
viru
serotyp
dengu
virus
transmit
aed
aegypti
mosquito
epidem
endem
v
section
vliver
diseas
due
infecti
agent
yellow
fever
prototyp
member
flavivirida
famili
group
plusstrand
singlestrand
rna
virus
yellow
fever
viru
singl
conserv
serotyp
seven
major
genotyp
reflect
distinct
region
western
africa
centraleast
africa
south
america
yellow
fever
viru
transmit
varieti
differ
aed
vector
caus
endem
epidem
outbreak
africa
south
america
approxim
case
yellow
fever
current
still
report
per
year
occur
africa
yellow
fever
travel
africa
south
america
becom
rare
sinc
introduct
routin
vaccin
spectrum
infect
yellow
fever
viru
rang
subclin
infect
lifethreaten
diseas
fever
jaundic
renal
failur
hemorrhag
usual
yellow
fever
initi
appear
acut
flulik
ill
sudden
onset
fever
myalgia
headach
easili
distinguish
acut
infect
hour
onset
serum
aminotransferas
start
rise
thu
herald
develop
jaundic
degre
liver
abnorm
stage
predict
sever
liver
diseas
later
cours
ill
next
period
remiss
last
hour
may
follow
initi
infect
patient
abort
infect
recov
stage
approxim
patient
enter
third
stage
intox
character
return
fever
prostrat
organ
dysfunct
lead
nausea
vomit
epigastr
pain
jaundic
oliguria
hemorrhag
diathesi
yellow
fever
differ
viral
caus
hepat
fact
serum
aspart
aminotransferas
ast
level
exceed
alanin
aminotransferas
alt
aminotransferas
level
proport
sever
diseas
direct
bilirubin
level
rang
mg
dl
level
higher
fatal
infect
recov
patient
diagnosi
yellow
fever
confirm
serolog
demonstr
specif
igm
enzymelink
immunosorb
assay
elisa
polymeras
chain
reaction
pcr
isol
viru
blood
liver
biopsi
recommend
high
risk
hemorrhag
outcom
infect
yellow
fever
viru
determin
second
week
onset
mani
patient
recov
rapidli
patient
progress
stage
intox
ultim
die
circulatori
shock
convalesc
may
associ
fatigu
sever
week
case
jaundic
elev
aminotransferas
level
may
persist
month
liver
patholog
vari
accord
stage
diseas
fatal
case
approxim
hepatocyt
undergo
coagul
necrosi
midzon
liver
lobul
affect
spare
cell
neighbor
central
vein
portal
tract
high
viral
load
detect
liver
sampl
patient
die
viral
antigen
locat
midzon
hepat
lobul
thu
indic
site
direct
viral
injuri
liver
injuri
character
eosinophil
degener
presenc
councilman
bodi
rare
intranuclear
inclus
bodi
torr
bodi
present
fatti
chang
may
promin
specimen
surviv
patient
liver
show
balloon
hepatocyt
regen
hyperplasia
multipl
multinucl
hepatocyt
portal
inflamm
consist
mainli
outbreak
caus
acut
infect
three
day
mosquito
bite
viru
spread
via
bloodstream
among
variou
organ
isol
frequent
liver
sampl
dengu
viral
antigen
detect
kupffer
cell
sinusoid
endotheli
cell
hepatocyt
dengu
viru
infect
usual
caus
flulik
ill
rashdengu
fever
hepatomegali
elev
serum
aminotransferas
usual
mild
common
dengu
viru
infect
clinic
sever
diseas
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
follow
secondari
infect
dengu
viru
differ
serotyp
thu
suggest
immun
respons
gener
previou
exposur
dengu
virus
may
enhanc
damag
trigger
secondari
dengu
infect
dhf
widespread
petechi
hemorrhag
togeth
multipl
organ
damag
dss
mostli
affect
children
younger
year
extens
capillari
leakag
sever
fluid
deplet
lead
hypovolem
shock
untreat
mortal
approach
fatal
case
dhf
liver
enlarg
pale
result
steatosi
show
multifoc
hemorrhag
microscop
focal
hepatocellular
necrot
area
seen
well
coalesc
perivenular
midzon
necrosi
councilman
bodi
rel
littl
inflammatori
cell
infiltr
suppos
liver
injuri
mediat
dengu
viru
infect
hepatocyt
kupffer
cell
vitro
infect
human
hepatoma
cell
line
dengu
viru
shown
induc
apoptot
cell
death
current
vaccin
dengu
viru
avail
treatment
support
dss
requir
intens
care
tabl
viral
hemorrhag
fever
affect
liver
patient
whose
treatment
begun
later
howev
toxic
teratogen
need
intraven
applic
expens
empir
therapi
ribavirin
advis
junin
viru
anoth
arenaviru
argentina
caus
viral
hemorrhag
fever
similar
lassa
fever
ribavirin
well
ribavirininterferon
combin
therapi
attempt
success
diseas
marburg
ebola
virus
nonseg
negativesens
singlestrand
rna
virus
belong
filovirida
viru
famili
among
virul
pathogen
caus
sever
hemorrhag
fever
fulmin
septic
shock
approv
therapi
current
avail
treat
devast
infect
ebola
marburg
virus
isol
marburg
viru
repres
member
singl
famili
wherea
ebola
isol
divid
differ
speci
zair
sudan
ivori
coast
reston
probabl
uganda
differ
virul
natur
reservoir
virus
still
remain
mysteri
although
suspect
virus
maintain
small
anim
bat
head
list
suspect
retrospect
analys
african
epidem
suggest
personperson
transmiss
occur
contact
viruscontamin
fluid
eg
blood
vomitu
fece
urin
marburg
viru
fever
first
detect
peopl
come
contact
african
green
monkey
import
uganda
mortal
first
outbreak
meanwhil
natur
outbreak
marburg
viru
ebola
fever
report
repeatedli
sever
western
central
african
region
fig
ebola
marburg
viru
cell
smaller
number
natur
killer
cell
biopsi
specimen
survivor
recoveri
phase
may
show
nonspecif
acinar
hepat
howev
hepat
reticular
architectur
disrupt
nonfat
case
heal
complet
without
residu
postnecrot
fibrosi
antivir
activ
yellow
fever
demonstr
sever
nucleosid
plant
alkaloid
ribavirin
inhibit
yellow
fever
viru
vitro
extrem
high
concentr
achiev
vivo
thu
treatment
support
highli
activ
attenu
live
vaccin
avail
induc
seroconvers
rate
greater
provid
high
level
protect
vaccin
given
pregnant
women
immunosuppress
individu
concern
risk
associ
live
attenu
viru
vaccin
infrequ
two
seriou
vaccinerel
complic
may
also
occur
immunocompet
person
form
enceph
term
yellow
feverassoci
neurotrop
diseas
syndrom
resembl
natur
infect
design
yellow
fever
vaccineassoci
viscerotrop
diseas
lassa
viru
envelop
singlestrand
biseg
rna
viru
belong
arenavirida
famili
natur
reservoir
multimamm
rat
mastomi
natalensi
excret
viru
urin
saliva
secret
human
presum
becom
infect
directli
via
contact
infect
rodent
excreta
fecalor
rout
inhal
contamin
air
risk
humanhuman
transmiss
low
serolog
evid
demonstr
infect
widespread
western
africa
clinic
overt
diseas
occur
fewer
overal
mortal
increas
intern
travel
sporad
result
import
lassa
fever
western
countri
challeng
diagnost
skill
physician
onset
infect
insidi
fever
myalgia
headach
malais
specif
featur
includ
ulcer
oral
caviti
bleed
gum
sore
throat
cough
pleurisi
wateri
diarrhea
lymphadenopathi
swell
liver
kidney
becom
pain
palpat
serum
aminotransferas
level
rise
jaundic
present
lassa
fever
liver
mottl
appear
liver
histolog
show
necrosi
without
inflamm
singl
hepatocyt
group
cell
stain
acidophil
found
harbor
abund
arenavirus
electron
microscopi
steatosi
cholestasi
wherea
lipofuscin
deposit
conspicu
elisa
lassa
viru
antigen
immunoglobulin
g
lgm
igg
antibodi
sensit
specif
africa
larg
replac
indirect
fluoresc
antibodi
test
western
countri
diagnosi
establish
reliabl
revers
transcript
pcr
rtpcr
support
therapi
often
necessari
addit
antivir
drug
ribavirin
effect
lassa
viru
infect
administ
earli
cours
ill
studi
sierra
leon
patient
high
risk
mortal
confirm
efficaci
ribavirin
treatment
lassa
fever
patient
die
intraven
ribavirin
administ
period
day
start
within
first
day
onset
fever
wherea
mortal
fortun
cchf
develop
one
five
peopl
infect
diseas
four
stage
incub
prehemorrhag
hemorrhag
convalesc
incub
take
day
fever
headach
myalgia
dizzi
develop
suddenli
facial
hyperemia
conjunct
occasion
diarrhea
also
note
stage
last
day
hemorrhag
period
short
day
common
bleed
site
nose
gastrointestin
tract
genitourinari
tract
respiratori
tract
survivor
convalesc
phase
begin
day
onset
diseas
rtpcr
method
choic
rapid
laboratori
confirm
cchf
viral
infect
leukopenia
thrombocytopenia
consist
laboratori
featur
rais
level
ast
alt
lactat
dehydrogenas
prolong
coagul
test
common
find
aminotransferas
level
seem
correl
sever
diseas
microscop
examin
liver
tissu
reveal
variabl
degre
hepatocellular
necrosi
hemorrhag
councilman
bodi
fatti
chang
kupffer
cell
hyperplasia
mild
mononuclear
portal
inflammatori
infiltr
treatment
option
limit
ribavirin
demonstr
antivir
activ
cchf
viru
vitro
anim
model
howev
thu
far
clinic
effect
ribavirin
demonstr
observ
studi
recent
outbreak
patient
sever
diseas
treat
success
ribavirin
day
mgkg
bodi
weight
initi
load
dose
mgkg
everi
hour
day
mgkg
everi
hour
day
hantavirus
prime
exampl
emerg
virus
member
genu
hantaviru
within
bunyavirida
famili
negativesens
singlestrand
rna
virus
carri
primarili
rodent
shed
viru
urin
saliva
fece
viru
inhal
human
aerosol
dri
rodent
excreta
unusu
circumst
transmit
via
rodent
bite
hantavirus
exist
multipl
serotyp
worldwid
differ
virul
consid
nonpathogen
wherea
certain
isol
produc
two
distinct
sever
syndrom
human
hantaviru
cardiopulmonari
syndrom
mostli
caus
isol
america
hemorrhag
fever
renal
syndrom
caus
isol
seoul
viru
dobrava
viru
puumala
viru
hantaan
viru
europ
asia
instanc
patient
hantaviru
hemorrhag
fever
suffer
sever
acut
hepat
wherea
renal
damag
rather
mild
furthermor
significantli
increas
preval
hantaviru
antibodi
report
patient
acut
hepat
unknown
caus
southwestern
china
patient
chronic
hepat
japan
howev
latter
studi
fail
detect
hantaviru
antibodi
patient
acut
hepat
thu
impli
rather
indirect
pathogenet
role
hantavirus
note
hantaviru
infect
observ
trigger
acut
exacerb
autoimmun
liver
diseas
mechan
propos
contribut
communityacquir
hepat
nevertheless
precis
role
hantaviru
infect
human
liver
diseas
still
await
clarif
analog
bunyavirus
hantaviru
sensit
ribavirin
although
approv
food
drug
administr
use
emerg
treatment
infect
still
relev
monkey
import
unit
state
philippin
die
ebola
viru
infect
outbreak
still
occur
western
africa
risk
undiagnos
patient
arriv
industri
countri
remain
real
inform
current
outbreak
avail
world
health
organ
websit
wwwwhointtop
haemorrhagicfeversviralen
diseas
caus
variou
marburg
ebola
viru
isol
result
similar
syndrom
differ
sever
case
fatal
rate
incub
period
day
may
exceed
day
symptomat
person
high
level
viru
blood
must
consid
contagi
appropri
safeti
precaut
taken
marburg
ebola
infect
typic
begin
abrupt
onset
fever
chill
gener
malais
featur
includ
weak
sever
headach
pain
muscl
trunk
lower
part
back
nausea
vomit
diarrhea
abdomin
pain
nonproduct
cough
pharyng
maculopapular
rash
upper
half
bodi
also
frequent
find
symptom
persist
worsen
prostrat
stupor
hypotens
dissemin
intravascular
coagul
eventu
lead
conjunctiv
hemorrhag
easi
bruis
bleed
venipunctur
site
mark
laboratori
abnorm
includ
strike
leukopenia
immatur
granulocyt
abnorm
lymphocyt
well
thrombocytopenia
filovirus
caus
multifoc
hepat
necrosi
thu
ast
alt
level
rise
rapidli
first
day
hypoproteinemia
proteinuria
may
also
present
hepat
patholog
similar
seen
lassa
viru
infect
spotti
widespread
necrosi
hepatocyt
minim
hepat
inflamm
cholestasi
abund
filoviru
particl
found
blood
phagocyt
endotheli
cell
hepatocyt
lymph
node
reticular
network
damag
survivor
marburg
ebola
hemorrhag
fever
requir
prolong
convalesc
suffer
mark
weak
fatigu
failur
regain
weight
mark
slough
skin
hair
loss
commonli
observ
rift
valley
fever
acut
vectorborn
zoonot
diseas
caus
rift
valley
fever
viru
belong
bunyavirida
famili
genu
phleboviru
viru
initi
describ
sheep
first
isol
human
kenya
diseas
widespread
subsaharan
africa
also
occur
egypt
mauretania
seneg
saudi
arabia
yemen
rift
valley
viru
transmit
sever
mosquito
speci
direct
contamin
infect
anim
patient
rift
valley
fever
symptom
sign
influenzalik
ill
fewer
patient
progress
sever
diseas
includ
hepat
enceph
retin
gener
hemorrhag
syndrom
crimeancongo
hemorrhag
fever
cchf
tickborn
viral
infect
occur
part
africa
asia
eastern
europ
middl
east
viru
belong
genu
nairoviru
bunyavirida
famili
isol
differ
region
show
consider
genet
divers
farmer
healthcar
worker
particular
risk
infect
chikungunya
arthropodborn
togaviru
initi
endem
western
africa
recent
year
spread
indian
ocean
island
southeast
asia
although
tradit
consid
diseas
tropic
subtrop
region
local
outbreak
chikungunya
even
record
northern
itali
intern
travel
chikungunya
infect
also
export
southeast
asia
indian
ocean
island
western
countri
infect
begin
abruptli
high
fever
symmetr
polyarthralgia
macular
maculopapular
rash
pruritu
bullou
skin
lesion
also
describ
previous
chikungunya
fever
consid
selflimit
diseas
howev
sever
complic
includ
acut
viral
hepat
death
report
recent
outbreak
particularli
elderli
patient
year
peopl
chronic
medic
problem
clinic
chikungunya
fever
must
differenti
dengu
fever
share
mani
symptom
featur
serolog
primari
diagnost
tool
clinic
practic
chikungunya
igm
antibodi
becom
detect
elisa
day
onset
symptom
viral
cultur
molecular
techniqu
valuabl
tool
research
set
although
interferon
alfa
ribavirin
exhibit
vitro
activ
chikungunya
viru
effect
specif
antivir
therapi
exist
thu
treatment
primarili
support
chikungunya
infect
current
prevent
vaccin
establish
organ
transplant
routin
therapeut
procedur
grow
use
anticanc
chemotherapi
recent
pandem
human
immunodefici
viru
hiv
infect
result
increas
awar
unusu
manifest
viral
infect
complic
immunosuppress
infect
occur
either
acut
diseas
primari
infect
sever
exacerb
latent
viral
persist
cytomegaloviru
common
opportunist
pathogen
caus
hepat
patient
druginduc
immunosuppress
hivinfect
patient
advanc
immunodefici
member
herp
famili
well
common
communityacquir
agent
adenoviru
also
import
caus
set
approxim
half
patient
faint
rash
infecti
mononucleosislik
syndrom
develop
week
month
primari
hiv
infect
sever
case
report
describ
hepatitislik
syndrom
patient
could
explain
concomit
infect
patient
complain
vomit
upper
abdomin
pain
hepatomegali
rise
aminotransferas
jaundic
elev
serum
alkalin
phosphatas
present
liver
diseas
resolv
spontan
histolog
report
avail
condit
autopsi
hepatomegali
found
approxim
two
third
patient
acquir
immunodefici
syndrom
aid
liver
biopsi
specimen
macrovesicular
steatosi
common
find
rare
instanc
could
becom
excess
hiv
repeatedli
detect
liver
particularli
kupffer
cell
endotheli
cell
situ
hybrid
immunohistochem
stain
thu
suggest
liver
might
import
site
hiv
replic
moder
chronic
lymphocyt
portal
inflamm
encount
liver
specimen
thought
reflect
hivassoci
reactiv
hepat
nonspecif
chang
associ
hiv
infect
becom
supersed
liver
patholog
caus
opportunist
infect
tumor
fig
illicit
drug
section
vliver
diseas
due
infecti
agent
nausea
vomit
abdomin
pain
leukopenia
coagulopathi
typic
oral
genit
vesicular
lesion
occur
third
patient
patient
also
dissemin
extrahepat
involv
lung
lymph
node
spleen
adren
gland
diagnosi
hsvrelat
hepat
must
establish
rapidli
via
detect
hsv
either
viral
isol
immunofluoresc
stain
preferenti
pcr
serolog
assay
rather
limit
applic
fatal
case
liver
enlarg
congest
autopsi
mottl
appear
multipl
white
yellow
foci
microscopi
reveal
irregular
parenchym
necrosi
littl
inflamm
margin
necrot
area
multinucl
hepatocyt
may
found
hepatocyt
may
contain
purpl
nuclear
inclus
bodi
surround
halo
organ
transplant
none
patient
surviv
liver
diffus
involv
wherea
three
seven
patient
focal
diseas
surviv
acyclovir
therapi
prompt
system
treatment
acyclovir
also
shown
reduc
hsvassoci
morbid
risk
seriou
complic
hivinfect
patient
addit
antihsv
prophylaxi
acyclovir
organ
transplant
markedli
reduc
hsv
reactiv
surgeri
acyclovir
resist
occur
immunocompromis
patient
neglig
immunocompet
subject
valacyclovir
prodrug
acyclovir
famciclovir
prodrug
penciclovir
similar
antivir
mechan
acyclovir
thu
hsv
isol
resist
acyclovir
also
resist
drug
cidofovir
foscarnet
altern
choic
treat
acyclovirresist
hsv
side
effect
greater
drug
acyclovir
varicellazost
viru
caus
chickenpox
well
shingl
latent
infect
reactiv
first
virem
phase
infect
vzv
replic
epithelia
gut
respiratori
tract
liver
endocrin
gland
secondari
viremia
lead
infect
skin
result
usual
rash
liver
diseas
rare
limit
patient
sever
immunodefici
anticanc
chemotherapi
corticosteroid
abus
current
also
side
effect
hiv
antiretrovir
therapi
herpesvirus
form
larg
famili
dna
virus
eight
member
caus
diseas
human
tabl
herp
simplex
viru
hsv
varicellazost
viru
vzv
epsteinbarr
viru
ebv
cytomegaloviru
cmv
human
herpesviru
type
directli
affect
liver
infect
human
usual
acquir
childhood
adolesc
herpesvirus
persist
lifelong
reactiv
induc
aggress
liver
diseas
immunosuppress
patient
unlik
herpesvirus
preval
kaposi
sarcomaassoci
viru
limit
found
saliva
may
serv
sourc
transmiss
sexual
probabl
also
vertic
mother
child
apart
kaposi
sarcoma
caus
castleman
diseas
bodi
caviti
lymphoma
sever
immunosuppress
patient
primari
herp
simplex
infect
produc
characterist
oral
genit
vesicular
lesion
erythemat
base
symptom
sever
fever
malais
mani
primari
infect
asymptomat
primari
infect
establish
viru
adopt
latent
state
persist
nerv
cell
bodi
dorsal
ganglia
reactiv
immunosuppress
fulmin
hepat
complic
infect
organ
transplant
treatment
hematolog
malign
frequent
underli
predisposit
individu
risk
includ
neonat
patient
take
steroid
hivinfect
patient
patient
cancer
myelodysplast
syndrom
fatal
hsvrelat
hepat
also
rare
report
immunocompet
adult
hsvrelat
hepat
high
mortal
resembl
septic
endotox
shock
jaundic
alway
present
ebv
nuclear
gene
two
type
ebv
identifi
show
diverg
preval
throughout
world
western
countri
time
preval
wherea
africa
two
ebv
genom
distribut
equal
pregnant
women
suscept
intrauterin
ebv
infect
rare
isol
case
may
lead
divers
congenit
anomali
includ
biliari
atresia
infant
young
children
primari
infect
common
frequent
asymptomat
wherea
adult
result
infecti
mononucleosi
syndrom
begin
malais
headach
lowgrad
fever
specif
symptom
pharyngitistonsil
swell
cervic
lymph
node
moder
highgrad
fever
develop
patient
peripher
blood
lymphocytosi
characterist
larg
abnorm
lymphocyt
blood
smear
nausea
vomit
anorexia
common
find
probabl
reflect
mild
hepat
accompani
infecti
mononucleosi
fever
approxim
patient
liver
histolog
show
diffus
lymphocyt
infiltr
sinusoid
focal
apoptot
hepatocyt
occasion
seen
fig
infiltr
may
atyp
must
care
differenti
leukemialymphoma
nonnecrot
hepat
granuloma
occasion
detect
treatment
risk
factor
complic
sever
vzv
infect
hepat
lesion
similar
herp
simplex
hepat
massiv
liver
necrosi
inclus
bodi
littl
inflamm
electron
microscopi
immunohistochemistri
reveal
abund
vzv
diagnosi
best
made
pcr
treatment
prophylaxi
similar
hsv
acyclovir
also
effect
vzv
addit
vzv
report
trigger
sever
autoimmun
hepat
epsteinbarr
viru
agent
account
acut
infecti
mononucleosi
syndrom
persist
lifelong
latent
state
result
dynam
interplay
viral
evas
strategi
host
immun
respons
howev
unlik
herpesvirus
reactivationassoci
diseas
promin
featur
chronic
ebv
diseas
still
ebv
potent
caus
varieti
malign
band
tcell
lymphoma
hodgkin
lymphoma
nasopharyng
carcinoma
transplant
patient
ebv
associ
aggress
lymphoprolif
diseas
ebv
shed
oral
secret
primari
ebv
infect
origin
oropharynx
base
genet
differ
section
vliver
diseas
due
infecti
agent
without
necrosi
present
cmv
inclus
bodi
cmv
immunostain
rare
detect
congenit
cmv
infect
observ
fewer
newborn
commonli
occur
mother
primari
cmv
infect
reactiv
cmv
pregnanc
approxim
neonat
symptom
birth
includ
hepatosplenomegali
jaundic
fetal
cmv
infect
also
associ
obstruct
biliari
diseas
neonat
hepat
giant
cell
transform
cholestasi
viral
inclus
bodi
cmv
infect
liver
endotheli
cell
kupffer
cell
hepatocyt
becom
swollen
may
contain
basophil
granul
cytoplasm
typic
intranuclear
amphophil
inclus
bodi
surround
clear
halo
resembl
owl
eye
may
also
present
see
fig
b
nuclear
cytoplasm
inclus
full
virion
cmvrelat
liver
diseas
common
caus
acut
viral
hepat
patient
organ
transplant
infect
may
result
reactiv
endogen
viru
immunosuppress
transmiss
transplant
organ
cmvposit
donor
transfus
blood
blood
product
liver
transplant
cmv
diseas
occur
month
cmv
infect
also
discuss
potenti
risk
factor
subsequ
develop
acut
chronic
reject
hand
reject
therapi
corticosteroid
bolus
may
trigger
reactiv
endogen
cmv
liver
biopsi
specimen
patient
posttranspl
cmv
hepat
usual
show
scanti
cmv
inclus
bodi
may
associ
small
foci
necrosi
inflamm
microabscess
see
fig
c
although
reactiv
cmv
also
common
sever
complic
hivposit
patient
advanc
immunodefici
usual
count
hepat
involv
seem
rather
minor
occasion
cmv
caus
sever
bile
duct
necrosi
also
major
caus
hiv
cholangiopathi
scleros
cholang
encount
rare
patient
termin
hivrel
immunodefici
de
novo
appear
cmv
antibodi
igm
class
fourfold
rise
igg
antibodi
consid
indic
activ
cmv
infect
immunocompet
individu
howev
serolog
unreli
immunocompromis
patient
replac
quantit
molecular
dna
amplif
assay
current
transplant
center
perform
cmv
surveil
weekli
quantit
determin
cmv
dna
also
administ
hyperimmun
antibodi
antivir
drug
cmv
prophylaxi
transplant
recipi
high
risk
acquir
cmv
diseas
howev
cmv
infect
diseas
may
still
develop
patient
immunodefici
cmv
hepat
treat
promptli
present
intraven
ganciclovir
oral
valganciclovir
week
treatment
choic
treatment
continu
reduc
dose
chemoprophylaxi
prolong
immunosuppress
anticip
fortun
ganciclovir
resist
seem
rather
rare
event
toxic
altern
cidofovir
foscarnet
larg
avoid
two
variant
infect
cell
also
cell
type
express
patient
infecti
mononucleosi
splenomegali
found
half
patient
hepatomegali
jaundic
uncommon
find
vast
major
patient
recov
period
week
fatigu
may
persist
sever
month
infect
patient
xlink
lymphoprolif
diseas
caus
mutat
gene
x
chromosom
particularli
vulner
ebv
may
suffer
fatal
infect
extens
liver
necrosi
patient
sever
immunodefici
lymphomatoid
granulomatosi
unusu
complic
ebv
infect
lead
granuloma
format
multipl
organ
includ
liver
may
requir
interferon
alfa
antivir
therapi
ebvassoci
lymphoprolif
disord
hepat
infiltr
immunoblast
hemophagocyt
syndrom
also
report
patient
hiv
infect
ebv
also
major
caus
agent
socal
posttranspl
lymphoprolif
diseas
ptld
organ
transplant
may
result
lymphocyt
infiltr
liver
organ
rang
benign
polyclon
bcell
prolifer
malign
bcell
lymphoma
ptld
occur
commonli
children
adult
relat
type
degre
immunosuppress
particularli
common
complic
ebvneg
individu
receiv
graft
ebvposit
donor
primari
ebv
infect
develop
result
immunosuppress
clinic
suspicion
ebv
infect
confirm
detect
heterophil
ebvspecif
antibodi
patient
infecti
mononucleosi
quantit
pcr
assay
lymphoprolif
disord
treatment
ebv
infect
primarili
support
corticosteroid
therapi
amelior
symptom
gener
recommend
ebv
infect
usual
selflimit
diseas
theoret
concern
suppress
immun
respons
viral
infect
potenti
caus
malign
diseas
nevertheless
corticosteroid
consid
individu
lifethreaten
complic
immin
liver
failur
acyclovir
inhibit
ebv
dna
polymeras
antivir
therapi
drug
shorten
viral
shed
fail
demonstr
convinc
clinic
benefit
even
patient
sever
acut
ebv
infect
acyclovir
affect
latent
ebv
infect
thu
anticanc
chemotherapi
bcell
monoclon
antibodi
possibl
reduct
immunosuppress
need
treat
ebvrel
lymphoprolif
disord
antivir
therapi
gener
effect
immunocompet
host
cmv
infect
asymptomat
caus
transient
minim
symptomat
acut
diseas
newborn
immunocompromis
patient
hiv
infect
cancer
solid
organ
bone
marrow
transplant
commonli
infect
cmv
may
suscept
develop
seriou
diseas
immunocompet
subject
primari
cmv
infect
produc
infecti
mononucleosislik
syndrom
associ
elev
serum
aminotransferas
level
mild
hepat
liver
histolog
may
show
focal
hepatocyt
bile
duct
damag
lymphocyt
infiltr
sinusoid
patient
epithelioid
granuloma
rash
fever
children
immunocompromis
individu
onset
diseas
usual
occur
sever
year
acquisit
kaposi
sarcoma
bodi
caviti
lymphoma
multicentr
castleman
diseas
typic
manifest
infect
bone
marrow
aplasia
multipl
myeloma
also
describ
associ
infect
lymphocyt
play
import
role
control
infect
explain
incid
diseas
increas
patient
transplant
aid
concept
also
support
observ
regress
kaposi
sarcoma
achiev
immunosuppress
reduc
patient
transplant
highli
activ
antiretrovir
therapi
haart
improv
immun
function
subject
aid
risk
factor
kaposi
sarcoma
predomin
manifest
diseas
multipl
homosexu
contact
hivinfect
men
transplant
set
male
sex
old
age
lung
transplant
autopsi
studi
kaposi
sarcoma
involv
liver
approxim
subject
aid
preval
declin
haart
hepat
kaposi
sarcoma
usual
part
widespread
cutan
viscer
diseas
may
rare
primari
manifest
fulmin
hepat
kaposi
sarcoma
also
observ
first
week
liver
transplant
fig
e
macroscop
dark
red
tumor
cm
diamet
may
seen
skin
liver
capsul
parenchyma
microscop
level
typic
lesion
mesh
spindl
celllik
tumour
cell
dilat
thinwal
vessel
diffus
plasma
cell
infrequ
mitosi
cluster
intracytoplasm
eosinophil
inclus
resembl
small
erythrocyt
characterist
featur
hepatosplenomegali
fever
weight
loss
typic
featur
multicentr
castleman
diseas
noncancer
prolifer
b
lymphocyt
see
fig
f
lymphocyt
patient
multicentr
castleman
diseas
kaposi
sarcoma
seem
cooper
thu
two
lesion
occasion
found
within
lymph
node
ascit
pleural
effus
may
initi
rais
suspicion
underli
liver
diseas
patient
bodi
caviti
lymphoma
differenti
presenc
abund
lymphoma
cell
aspir
fluid
see
fig
g
also
caus
solid
organ
lymphoma
liver
lead
diffus
sinusoid
accumul
b
lymphocyt
reconstitut
immun
function
primari
goal
treatment
diseas
apart
haart
hiv
infect
may
achiev
use
antiprolif
mtor
mammalian
target
rapamycin
inhibitor
immun
suppress
transplant
immun
stimul
imiquimod
interferon
alfa
chemotherapi
liposom
anthracyclin
paclitaxel
kaposi
sarcoma
rituximab
castleman
diseas
lymphoma
potent
treatment
option
ganciclovir
cidofovir
foscarnet
adefovir
lobucavir
acyclovir
show
vitro
activ
block
replic
cell
line
doubleblind
placebocontrol
crossov
trial
valganciclovir
reduc
oropharyng
shed
receptor
though
genet
clearli
distinct
anoth
share
mani
featur
primari
infect
either
viru
commonli
occur
young
age
lead
febril
ill
known
exanthema
subitum
roseola
infantum
pityriasi
rosea
reflect
primari
infect
although
spectrum
diseas
caus
later
fulli
known
virus
link
varieti
differ
syndrom
enceph
multipl
sclerosi
pneumon
infecti
mononucleosislik
condit
postinfecti
drug
hypersensit
well
lymphoprolif
disord
system
diseas
immunocompromis
patient
also
caus
hepat
occasion
result
liver
failur
neonat
young
infant
moreov
dna
antigen
detect
signific
proport
children
adult
underw
transplant
acut
liver
failur
unknown
caus
note
two
patient
infect
immin
liver
failur
infect
control
success
valganciclovir
liver
transplant
plu
ganciclovir
respect
hepat
caus
also
complic
organ
transplant
acut
liver
failur
coinfect
hepat
b
c
virus
identifi
risk
factor
reactiv
patient
liver
transplant
note
reactiv
seem
significantli
increas
mortal
live
relat
liver
transplant
recipi
reactiv
also
reactiv
cmv
infect
lead
symptomat
diseas
liver
transplant
patient
addit
associ
autoimmun
postinfantil
giant
cell
hepat
well
giant
cell
transform
bile
duct
cell
seroconvers
least
fourfold
rise
igg
antibodi
titer
pair
sampl
consid
diagnost
infect
serolog
distinguish
variant
may
also
crossreact
igm
antibodi
develop
within
week
infect
unreli
marker
approxim
healthi
subject
may
posit
igm
test
given
time
detect
tissu
sampl
virusspecif
monoclon
antibodi
prefer
method
diagnos
infect
quantit
dna
amplif
assay
immunocompet
patient
caus
benign
selflimit
infect
requir
specif
antivir
treatment
nevertheless
foscarnet
activ
vitro
wherea
unlik
may
rel
resist
ganciclovir
cidofovir
may
therapeut
altern
resist
isol
identifi
although
vitro
studi
anecdot
report
transplant
set
seem
suggest
benefici
effect
human
infect
antivir
therapi
yet
evalu
control
trial
potenti
malign
transform
although
primari
infect
caus
coryza
pneumonia
otiti
media
young
children
acut
diarrheal
ill
caus
subgroup
f
type
adenovirus
adenovirus
persist
human
tissu
prolong
period
caus
varieti
clinic
syndrom
immunocompromis
individu
includ
seriou
hepat
adenovir
hepat
occur
congenit
acquir
immunodefici
syndrom
may
fatal
adenovirus
worldwid
distribut
caus
febril
diseas
infant
young
children
serotyp
distinguish
subdivid
six
subgroup
f
typic
syndrom
includ
conjunct
upper
respiratori
tract
infect
pharyng
asymptomat
derang
biochemistri
fulmin
hepat
failur
loss
immun
control
consid
respons
hepat
associ
opportunist
viral
infect
rather
similar
mechan
may
oper
sever
acut
respiratori
syndrom
sar
associ
hepat
character
focal
lobular
lymphocyt
infiltr
final
collater
damag
propos
influenza
infect
reflect
expans
virusspecif
cell
gener
outsid
liver
may
trigger
tcelldepend
hepat
even
viral
antigen
appar
absent
liver
kupffer
cell
play
pivot
role
process
take
present
viral
antigen
coordin
lymphocyt
recruit
possibl
becom
activ
lymphocyt
induc
hepatocellular
apoptosi
tcell
expans
occur
mani
viral
infect
bystand
mechan
may
contribut
hepat
mani
extrahepat
infect
import
implic
liver
pathobiolog
influenza
virus
repres
three
genera
orthomyxovirida
famili
gener
influenza
virus
associ
sever
diseas
human
influenza
b
c
virus
influenza
subdivid
respect
genet
variat
hemagglutinin
h
neuraminidas
individu
adenovir
hepat
particular
problem
pediatr
liver
transplant
identifi
pediatr
liver
transplant
recipi
patient
die
requir
retransplant
patient
recov
decreas
immunosuppress
therapi
transmiss
latent
adenoviru
donat
organ
seem
potenti
risk
factor
complic
sign
symptom
adenovir
hepat
resembl
hsv
infect
consist
massiv
elev
aminotransferas
level
sever
coagulopathi
extens
area
liver
cell
necrosi
littl
inflamm
intranuclear
inclus
bodi
fig
date
proven
therapi
adenovir
hepat
exist
ribavirin
may
help
select
case
liver
affect
part
gener
infect
virus
primarili
target
tissu
liver
adenoviru
influenza
liver
involv
rang
section
vliver
diseas
due
infecti
agent
present
liver
analog
influenza
infect
host
immun
respons
may
contribut
liver
damag
recent
sar
outbreak
ribavirin
kaletra
babydos
ritonavirlopinavir
use
experiment
therapi
limit
success
measl
caus
morbilliviru
paramyxovirida
famili
acut
febril
ill
typic
rash
current
prevent
vaccin
measl
associ
divers
complic
pneumon
subacut
scleros
panenceph
caus
signific
mortal
thirdworld
countri
patient
immunodefici
liver
dysfunct
increasingli
recogn
complic
measl
children
adult
may
becom
promin
featur
patient
atyp
measl
partial
immun
measl
viru
hepat
abnorm
note
occur
frequent
adult
patient
primari
infect
children
two
pattern
hepat
dysfunct
encount
asymptomat
elev
aminotransferas
resolv
within
day
rare
prolong
cholestasi
jaundic
may
appear
measl
begin
reced
liver
tissu
steatosi
portal
inflamm
focal
necrosi
report
viral
inclus
giant
cell
rare
seen
observ
child
congenit
immunodefici
addit
measl
incrimin
trigger
autoimmun
hepat
paramyxoviru
particl
also
report
sever
patient
syncyti
giant
cell
hepat
howev
natur
particl
thu
far
remain
elus
childhood
rubella
appar
associ
signific
liver
diseas
nonetheless
viru
propos
caus
neonat
giant
cell
hepat
may
also
accompani
necrosi
cholestasi
lymphocyt
infiltr
histolog
examin
group
b
coxsackieviru
infect
caus
liver
diseas
part
seriou
multisystem
infect
young
children
also
rare
adult
liver
histolog
show
hemorrhag
necrosi
neonat
wherea
adult
swollen
hepatocyt
bile
stasi
mix
infiltr
mononuclear
polymorph
leukocyt
portal
tract
sinusoid
observ
human
parvoviru
nonenvelop
singlestrand
dna
viru
belong
erythroviru
genu
parvovirida
famili
human
known
host
produc
wide
rang
differ
syndrom
immunocompet
peopl
infect
asymptomat
suffer
nonspecif
malais
muscl
pain
fever
second
week
may
follow
rash
arthralgia
pancytopenia
edema
quarter
infect
patient
experiment
observ
remark
rise
liver
enzym
occur
pyrexia
settl
thu
suggest
liver
damag
mediat
host
immun
respons
rather
viral
infect
liver
propos
immunemedi
liver
damag
may
also
caus
elev
aminotransferas
viral
respiratori
infect
respiratori
syncyti
viru
although
cardiovascular
effect
hepat
ischemia
must
consid
sever
ill
patient
well
novel
coronaviru
sarscoronaviru
sarscov
caus
sar
result
outbreak
sever
infect
lung
gastrointestin
tract
far
east
canada
also
involv
organ
approxim
patient
elev
liver
enzym
onset
infect
elev
level
develop
later
addit
patient
normal
liver
enzym
initi
evalu
overal
patient
elev
liver
enzym
level
ill
jaundic
observ
less
patient
patient
aminotransferas
level
start
rise
toward
end
first
week
peak
end
second
week
resolut
sar
aminotransferas
normal
spontan
major
patient
sever
liver
damag
alt
five
time
upper
limit
normal
observ
frequent
male
patient
signific
comorbid
condit
elev
serum
creatinin
level
role
concomit
hepat
b
diseas
sever
controversi
howev
close
relationship
sever
hepat
dysfunct
degre
pulmonari
damag
outcom
sar
thu
high
alt
level
appear
independ
predictor
sever
diseas
wors
outcom
histopatholog
studi
reveal
mark
apoptosi
hepatocyt
conspicu
presum
compensatori
mitot
activ
hepatocyt
also
show
balloon
mild
moder
lymphocyt
infiltr
describ
portal
tract
liver
lobul
although
sarscov
rtpcr
consist
posit
liver
specimen
immunohistochemistri
electron
microscopi
fail
detect
viral
antigen
viral
particl
sever
biopsi
postmortem
studi
thu
small
amount
sarscov
seem
schoolag
children
occasion
also
adult
arthropathi
aplast
anemia
complic
adult
fetal
infect
gestat
caus
hydrop
fetali
associ
mark
damag
liver
hepatocyt
balloon
swollen
nuclei
harbor
eosinophil
nuclear
inclus
bodi
addit
erythroidmyeloid
precursor
greatli
expand
sinusoid
parvoviru
also
identifi
caus
acut
hepat
incrimin
underli
caus
acut
liver
failur
anemia
howev
subsequ
studi
could
confirm
parvoviru
caus
fulmin
hepat
failur
torquetenoviru
ttv
initi
identifi
novel
viru
three
five
patient
posttransfus
hepat
develop
found
neg
known
hepat
virus
ttv
classifi
genu
anelloviru
attach
famili
torquetenominiviru
relat
virus
smaller
genom
provision
design
small
anellovirus
member
genu
ttv
subdivid
five
phylogenet
group
coinfect
sever
genotyp
common
ttv
variant
design
sen
viru
name
patient
isol
soon
discoveri
becam
clear
ttv
viremia
occur
frequent
healthi
gener
popul
worldwid
thu
clinic
signific
ttv
infect
remain
uncertain
inocul
chimpanze
ttv
led
viremia
caus
hepat
moreov
sever
studi
ttv
transmiss
fail
establish
consist
relationship
ttv
viremia
elev
serum
aminotransferas
level
nevertheless
exclud
ttv
respons
acut
hepat
subset
patient
ttv
seem
caus
rather
mild
form
hepat
likewis
studi
also
could
confirm
consist
associ
persist
ttv
presenc
biochem
histolog
hepat
abnorm
varieti
differ
clinic
set
ttv
infect
seem
trigger
autoimmun
hepat
casecontrol
studi
fail
establish
ttv
independ
risk
factor
hepatocellular
carcinoma
taken
togeth
seem
like
initi
report
increas
ttv
preval
patient
chronic
liver
diseas
reflect
share
risk
factor
infect
liver
damag
rather
ttv
caus
liver
diseas
